In an effort to revolutionize the healthcare industry, AstraZeneca has launched Evinova, a new health-tech business focused on providing clinical trial design and study delivery solutions. This separate business aims to offer scalable solutions to trial sponsors, clinical research organizations, care teams, and patients. By doing so, Evinova expects to reduce the time and cost of developing new medicines, bring care closer to patients’ homes, and decrease the burden on health systems.
To bring Evinova’s innovative solutions to a wider audience, AstraZeneca has formed major collaborations with Parexel and Fortrea. These partnerships will allow Evinova’s digital health solutions to be made available to a broad customer base, supporting the company’s mission of improving patient care and driving healthcare transformation while reducing carbon emissions.
AstraZeneca’s Chief Executive, Pascal Soriot, expressed his confidence in Evinova’s ability to combine scientific expertise with AI-enabled digital technologies at scale. He believes this combination offers a real opportunity for positive change in the healthcare industry.
For more information about Evinova or any other inquiries related to this topic, please contact Michael Susin at michael.susin@wsj.com.